Pharmaceutical News

RSS

Quick-Med expands and strengthens NIMBUS technology intellectual property

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 7,790,217 entitled "Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate."

8 Sep 2010

USPTO awards Medicis new patent for SOLODYN Extended Release Tablets

Medicis today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,790,705 related to the use of SOLODYN® (minocycline HCI, USP) Extended Release Tablets. The new patent, entitled "Minocycline Oral Dosage Forms for the Treatment of Acne," relates to the use of dosage forms of SOLODYN which provide approximately 1 mg/kg dosing based on the body weight of the person, and expires in 2027.

8 Sep 2010

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Enobia Pharma today provided an update on key developments in its comprehensive effort to develop ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia. Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.

8 Sep 2010

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.

8 Sep 2010

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Perrigo Company announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically integrate this product with their own API.

8 Sep 2010

AVAC welcomes new Global HIV Vaccine Enterprise Scientific Strategic Plan

AVAC welcomes the new Global HIV Vaccine Enterprise Scientific Strategic Plan, released today, as a critical document that the field must implement as part of ongoing efforts to improve coordination, efficiency and transparency to quickly capitalize on recent advances in AIDS vaccine research.

8 Sep 2010

Experts gathered for UNAIDS, WHO meeting recommend follow-up studies of ARV-containing microbicide gel start soon

Experts gathered at a joint meeting of UNAIDS and the WHO last week called for two additional clinical trials to test the effectiveness and safety of a microbicide vaginal gel containing the antiretroviral tenofovir, which previous studies have shown reduces the risk of HIV transmission in women who used it before and after sex by 39 percent, PANA/Afrique en ligne reports (9/5).

8 Sep 2010

Oxygen Biotherapeutics offers traumatic brain injury trials for Israeli soldiers

Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced that Israeli soldiers who suffer severe traumatic brain injury (TBI) can be enrolled in the company's Phase II-b STOP-TBI trials at clinical sites in Israel.

8 Sep 2010

La Jolla Pharmaceutical seeks clinical product for lupus treatment

La Jolla Pharmaceutical Company provided an update today that the Company is actively seeking and evaluating potential pharmaceutical products for in-licensing or acquisition and has engaged consultants to determine whether there is any potential for the further development of Riquent for the treatment of lupus.

8 Sep 2010

Global Fund investigates allegations that donated malaria drugs were stolen, resold in some African countries

After recent research found that some donated malaria drugs are being stolen and sold commercially in several African countries, the Global Fund to Fight AIDS, Tuberculosis and Malaria Communications Director Joe Liden said the group is looking into the situation "in a number of countries," PBS' NewsHour's blog, "The Rundown" reports.

8 Sep 2010

Forest Laboratories' ceftaroline fosamil receives FDA Advisory Committee approval for CABP and cSSSI

Forest Laboratories, Inc. announced that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted 21 - 0 in favor of approval of ceftaroline fosamil for the treatment of community acquired bacterial pneumonia (CABP) and voted 18 - 0 in favor of approval for complicated skin and skin structure infections (cSSSI).

8 Sep 2010

Fluctuation in PCV-7 vaccine dosing time increases pneumococcal serotype 19A strains: Study

Infants who received heptavalent pneumococcal conjugate vaccination (PCV-7) at 2, 4, and 11 months were more likely than unvaccinated controls to have nasopharyngeal (in the nasal passages and upper part of the throat behind the nose) acquisition of pneumococcal serotype 19A, a leading cause of respiratory pneumococcal disease, according to a study in the September 8 issue of JAMA.

8 Sep 2010

BMJ investigation raises concern on rosiglitazone diabetes drug safety

A BMJ investigation into the top-selling diabetes drug rosiglitazone (Avandia) raises concerns about its safety and the whole system by which drugs are evaluated, regulated, and promoted around the world.

8 Sep 2010

CDC ramps up production of new three-in-one flu vaccine

Health officials say that there will be plenty of flu vaccine available this year, now that the H1N1 pandemic has ended, The Washington Post reports. "The World Health Organization declared an end to the pandemic last month, based on indications that the H1N1 flu was transitioning to a more seasonal virus. Unlike last year, when there was one vaccine for H1N1 flu and another for seasonal flu, this year's vaccine is a 'three-in-one' that includes protection against H1N1 as well as two other strains."

8 Sep 2010

Alzheimer's disease drug market to increase from $4.3 billion to $13.3 billion in 2019: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the emergence of new agents that have the potential to affect disease progression, the Alzheimer's disease drug market will more than triple, from $4.3 billion in 2009 to $13.3 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

8 Sep 2010

Watson Laboratories receives FDA approval for Zarah tablets

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Zarah (drospirenone and ethinyl estradiol tablets) 3 mg/0.03 mg, the generic equivalent to Bayer's Yasmin.

7 Sep 2010

Oragenics launches oral care probiotic products through GNC Stores

Florida-based biopharmaceutical company Oragenics, Inc. announced today that its oral care probiotic EvoraPlus® is now expected to be available at corporate-owned GNC stores nationwide. In addition, GNC has included Oragenics' oral care probiotic for children, EvoraKids™, in its concept stores and on GNC.com.

7 Sep 2010

Bayer Consumer Care introduces One A Day Menopause Formula to help address hot flashes

September is Menopause Awareness Month and women starting the transition into menopause have more information and resources than ever to start taking control of their menopause symptoms. Bayer Consumer Care now introduces One A Day® Menopause Formula, a complete multivitamin with soy isoflavones to help address hot flashes and mild mood changes.

7 Sep 2010

Somaxon's Silenor now commercially available in U.S.

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that Silenor® (doxepin) now is commercially available by prescription in the United States. Somaxon has implemented a wholesale and retail stocking program to disseminate Silenor 3 mg and 6 mg dosepacks to pharmacies across the United States. Silenor is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

7 Sep 2010

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the company received verbal notice on Friday, September 3, 2010 from the U.S. Food and Drug Administration (FDA) that the IDX184 and IDX320 programs have been placed on clinical hold.

7 Sep 2010

Pharmaceutical News

Quick-Med expands and strengthens NIMBUS technology intellectual property

USPTO awards Medicis new patent for SOLODYN Extended Release Tablets

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

AVAC welcomes new Global HIV Vaccine Enterprise Scientific Strategic Plan

Experts gathered for UNAIDS, WHO meeting recommend follow-up studies of ARV-containing microbicide gel start soon

Oxygen Biotherapeutics offers traumatic brain injury trials for Israeli soldiers

La Jolla Pharmaceutical seeks clinical product for lupus treatment

Global Fund investigates allegations that donated malaria drugs were stolen, resold in some African countries

Forest Laboratories' ceftaroline fosamil receives FDA Advisory Committee approval for CABP and cSSSI

Fluctuation in PCV-7 vaccine dosing time increases pneumococcal serotype 19A strains: Study

BMJ investigation raises concern on rosiglitazone diabetes drug safety

CDC ramps up production of new three-in-one flu vaccine

Alzheimer's disease drug market to increase from $4.3 billion to $13.3 billion in 2019: Report

Watson Laboratories receives FDA approval for Zarah tablets

Oragenics launches oral care probiotic products through GNC Stores

Bayer Consumer Care introduces One A Day Menopause Formula to help address hot flashes

Somaxon's Silenor now commercially available in U.S.

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News